Anna Kraus and Paige Jennings write:
As we discussed in two prior posts (here and here), the April 29, 2015, draft House 21st Century Cures bill would make several changes to federal health privacy law. This post focuses on provisions that would relax limitations on payment for PHI disclosed for research purposes and that would expand the purposes for which covered entities may disclose PHI to FDA-regulated entities without individual authorization. We also discuss several provisions included in a prior draft of the Cures bill that have been excluded from the April 29 draft.
Read more on Covington & Burling Inside Privacy.